AmStem International, Inc. Retains Hawk Associates for Strategic Investor Relations
Published: May 24, 2010
SAN FRANCISCO, CA--(Marketwire - May 24, 2010) - AmStem International (OTCBB: AMST), an international biotechnology company operating in the high-tech field of stem cell based therapy with emphasis on regenerative medicine and treatments, announced today that it has retained the services of Hawk Associates for strategic investor relations.
David Stark, President of AmStem International, said, "We believe that Hawk Associates is one of the premier investor relations firms helping companies successfully communicate their stories to Wall Street and the broader investment community. We have retained Hawk Associates as a strategic advisor to help us build shareholder value. Hawk specializes in communicating with investors by understanding how to attract attention for small companies like ours. The Wall Street branding and investor relations expertise that Hawk provides will be an excellent complement to our company's initiatives. We look forward to working with Frank Hawkins and his team at Hawk."
Hawk Associates CEO Frank Hawkins said, "AmStem is a leading edge company in one of the most promising new technologies of our time. Unfortunately, it has not had the exposure that it deserves. The acquisition of Histostem in Korea immediately transformed the company into a potential major player in the stem cell area. The company is cleverly using cosmetic sales to avoid the debt and dilution often associated with biotech startups. For investors, this alone sets the company apart from many others in the industry."
"We are looking forward to working with AMST to help build a cohesive branding and messaging strategy that will resonate with investors. This is a unique company with a refreshing story. We are confident we can optimize the company's message and help increase its long-term valuation," Hawkins said.
About AmStem International
AmStem is an international biotechnology company operating in the high-tech field of stem cell-based therapy with emphasis on regenerative medicine and treatments. The company, which operates one of the world's largest cord blood banks, is a pioneer in both medical and cosmetic treatments using stem cells isolated from human umbilical cord blood and nurtured to multipotent stem cells. Actively pursuing new applications in both medicine and cosmetics, AmStem has successfully treated patients with a number of serious diseases and has numerous clinical trials in progress. Its main cosmetic product is the facial cream SteMixx.
For more information contact AmStem CFO Andrew Norstrud at (813) 283.2556 or Tom Fox at Hawk Associates at (305) 451.1888. For additional information about AMST visit: http://amsteminc.com or www.hawkassociates.com.